Cytokinetics jumps as heart disease drug meets goals in late-stage trial

Bristol-Myers Squibb Co

05/05/2026 14:46

Updates

** Shares of drugmaker Cytokinetics CYTK.O climb 16.5% to $76.95, highest in over two years

** Co says its heart disease drug met the dual goals of a late-stage trial in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, an inherited heart disorder where the heart muscle is thickened

** The drug, aficamten, is approved under the brand name Myqorzo for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, which causes excessive thickening of the heart muscle and obstructs blood flow from the left ventricle

** Today's results could also solidify its status as the preferred HCM therapy over Bristol Myers Squibb's BMY.N Camzyos, Truist says

** Up to last close, CYTK stock up 4% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))